Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/5/2025 | $2.00 → $1.00 | Outperform → Market Perform | Leerink Partners |
| 6/17/2024 | $10.00 | Buy | H.C. Wainwright |
| 4/30/2024 | $5.00 | Outperform | Leerink Partners |
| 3/7/2023 | $3.00 | Hold | Jefferies |
| 8/12/2022 | $10.00 | Overweight | Piper Sandler |
S-8 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Filer)
10-Q - LEXICON PHARMACEUTICALS, INC. (0001062822) (Filer)
8-K - LEXICON PHARMACEUTICALS, INC. (0001062822) (Filer)
– Results support advancement of 10 mg dose into Phase 3 development – – End-of-Phase 2 meeting request accepted by U.S. FDA; partnership discussions progressing – THE WOODLANDS, Texas, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced the Company presented additional clinical data and program updates from its Phase 2 pilavapadin program at the 19th Annual Pain Therapeutics Summit. These data follow the topline results from the Phase 2b PROGRESS study of pilavapadin in diabetic peripheral neuropathic pain (DPNP) announced in March of 2025, which identified 10 mg once daily as the most clinically meaningful and appropriate dose to advance into
THE WOODLANDS, Texas, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Yesterday, Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) hosted and participated in a roundtable discussion with experts to explore how to enhance current and future legislative and policy efforts to better meet the needs of Americans suffering from chronic pain. The perspectives of clinicians, patient advocacy groups, and individuals were shared during the half-day meeting conducted at the Biotechnology Innovation Organization (BIO) headquarters in Washington, DC. According to the U.S. Pain Foundation, approximately 50 million Americans suffer from chronic pain and pain conditions cost as much as $635 million yearly in direct health c
Data obtained from ongoing third-party funded, investigator-sponsored trials have been submitted in effort to address the December 2024 complete response letter Company seeks alignment on reasonable path forward for Zynquista NDA resubmission FDA feedback from Type D meeting now expected during the fourth quarter THE WOODLANDS, Texas, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced an update to the previous submission of additional clinical data to the U.S. Food and Drug Administration (FDA) from ongoing third-party funded, investigator-initiated studies supporting the potential resubmission of the New Drug Application for Zynquista®
4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)
4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)
4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)
Submission status for LEXICON PHARMACEUTICALS INC's drug INPEFA (ORIG-1) with active ingredient SOTAGLIFLOZIN has changed to 'Approval' on 05/26/2023. Application Category: NDA, Application Number: 216203, Application Classification: Type 1 - New Molecular Entity
3 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)
3 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)
4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)
Leerink Partners downgraded Lexicon Pharma from Outperform to Market Perform and set a new price target of $1.00 from $2.00 previously
H.C. Wainwright initiated coverage of Lexicon Pharma with a rating of Buy and set a new price target of $10.00
Leerink Partners initiated coverage of Lexicon Pharma with a rating of Outperform and set a new price target of $5.00
THE WOODLANDS, Texas, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced the appointment of Scott Coiante as senior vice president and chief financial officer, effective today, January 2, 2025. Mr. Coiante is a senior finance executive with more than 35 years of experience in the life science and pharmaceutical industries. He joins Lexicon from Agile Therapeutics, where he served as the senior vice president, chief financial officer and treasurer of Agile Therapeutics Inc. from August 2023 to August 2024, as well as from 2011-2019. "I am pleased to join Lexicon at this pivotal moment for the company and eager to contribute to its
THE WOODLANDS, Texas, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that Ivan H. Cheung has been elected to its Board of Directors. Mr. Cheung is a biopharmaceutical executive with more than 25 years of experience in the healthcare industry and a proven track record of shareholder value creation. He is currently the chief executive officer and a director of NextPoint Therapeutics, and he has served as senior advisor to TPG Growth – a growth investing platform within global asset manager TPG – since September 2023. "I am honored to join the Lexicon Board of Directors at this pivotal moment in the company's history, and to support its mis
THE WOODLANDS, Texas, July 08, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that the Lexicon Board of Directors has appointed Mike Exton, Ph.D. as chief executive officer and director of Lexicon. Dr. Exton succeeds Lonnel Coats who, as previously announced, retired effective July 7, 2024. Dr. Exton most recently served as the global cardiometabolic therapeutic head at Novartis. "I am confident that Mike is the right person to serve as Lexicon's next chief executive officer at this critical time for the company," said Ray Debbane, chairman of Lexicon's board of directors. "He is an inspiring leader with a demonstrated track record of success, includi
Partnership discussions for pilavapadin remain underway following Phase 2b PROGRESS study results IND-enabling studies of LX9851 for obesity and related disorders on track for completion in 2025 with licensee Novo Nordisk expected to submit IND Enrollment completion for SONATA Phase 3 study in both obstructive and non-obstructive hypertrophic cardiomyopathy (HCM) on target for 2026 Conference call and webcast at 8:30 am ET THE WOODLANDS, Texas, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), today reported financial results for the three months ended June 30, 2025, and provided an update on key corporate milestones and accomplishments. "We continue t
THE WOODLANDS, Texas, July 23, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced the Company will release its second quarter 2025 financial results on Wednesday, August 6, 2025, prior to market open. Management will conduct a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) that day to discuss the financial results and to provide a business update. Participants can access the conference call live via webcast on the Events page of the Company's website at https://investors.lexpharma.com/. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin to join the call. An archived version of the webcast
Company had a strong start to 2025, emerging as an R&D-focused organization Exclusive license agreement with Novo Nordisk for LX9851 executed; IND-enabling studies on track for completion in 2025 Phase 2b PROGRESS study confirmed 10 mg pilavapadin as appropriate dose for advancement into Phase 3 development for diabetic peripheral neuropathic pain Conference call and webcast at 5:00 pm ET THE WOODLANDS, Texas, May 13, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), today reported financial results for the three months ended March 31, 2025, and provided an update on key corporate milestones and accomplishments. "We began 2025 delivering on three of our goals for
SC 13D/A - LEXICON PHARMACEUTICALS, INC. (0001062822) (Subject)
SC 13G/A - LEXICON PHARMACEUTICALS, INC. (0001062822) (Subject)
SC 13G/A - LEXICON PHARMACEUTICALS, INC. (0001062822) (Subject)